Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05679401 · ClinicalTrials.gov registry record · Phase 3
A Study With Imlifidase in Anti-GBM Disease
A Phase 3 study, sponsored by Hansa Biopharma AB.
- Terminated
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT05679401: Clinical Trial Phase 3 study, sponsored by Hansa Biopharma AB.
NCT05679401 is a Phase 3 study that was terminated before completion, run by Hansa Biopharma AB. The registered enrollment target is 50 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05679401, a Phase 3 study, was terminated before completion, sponsored by Hansa Biopharma AB.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
Interventions
- DRUG Glucocorticoids
- DRUG Imlifidase
- PROCEDURE Plasma exchange (PLEX)
- DRUG Cyclophosphamide (CYC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 3 |
Why NCT05679401 stopped before completion
NCT05679401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 4 interventions - of which Glucocorticoids is the first listed.
NCT05679401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05679401 about?
NCT05679401 is a clinical study titled "A Study With Imlifidase in Anti-GBM Disease". An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.
What is the current status of trial NCT05679401?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-12-22. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT05679401?
The interventions under investigation include: Glucocorticoids (DRUG), Imlifidase (DRUG), Plasma exchange (PLEX) (PROCEDURE), Cyclophosphamide (CYC) (DRUG).
Who is sponsoring clinical trial NCT05679401?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05679401's enrollment target sits among peer trials
50 1844th of 2000 higher than 141 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI